Fortrea Inc. (FTRE)
5.21
0.03 (0.58%)
At close: Apr 14, 2025, 12:51 PM
0.58% (1D)
| Bid | 5.18 |
| Market Cap | 469.49M |
| Revenue (ttm) | 2.7B |
| Net Income (ttm) | -305.3M |
| EPS (ttm) | -3.03 |
| PE Ratio (ttm) | -1.72 |
| Forward PE | 13.26 |
| Analyst | Hold |
| Ask | 5.22 |
| Volume | 560,775 |
| Avg. Volume (20D) | 2,129,706 |
| Open | 5.37 |
| Previous Close | 5.18 |
| Day's Range | 5.15 - 5.55 |
| 52-Week Range | 4.95 - 39.48 |
| Beta | 2.08 |
About FTRE
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2023
Employees 15,500
Stock Exchange NASDAQ
Ticker Symbol FTRE
Website https://www.fortrea.com
Analyst Forecast
According to 11 analyst ratings, the average rating for FTRE stock is "Hold." The 12-month stock price forecast is $21, which is an increase of 303.46% from the latest price.
Stock ForecastsNext Earnings Release
Fortrea Inc. is scheduled to release its earnings on May 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
-19.22%
Fortrea Holdings shares are trading lower after Ba...
Unlock content with
Pro Subscription
1 month ago
-25.05%
Fortrea shares are trading lower after the company reported worse-than-expected Q4 FY24 financial results and 2025 guidance.
